Privi Speciality Chemicals Limited (PSCL) announced the outcomes of its Board Meeting held on June 14, 2025:

• The Board decided not to proceed with the previously approved capital raising of up to ₹1,000 crore via Qualified Institutions Placement (QIP). This decision was made due to the company's improved performance and sufficient cash accruals to meet capital expenditure requirements.
• The Board approved a scheme of amalgamation of Privi Fine Sciences Private Limited (PFSPL), a related party, and Privi Biotechnologies Private Limited (PBPL), a wholly owned subsidiary, with PSCL.
• Rationale for the amalgamation includes achieving merger and consolidation synergies, preserving and creating value for stakeholders, enhancing and strengthening PSCL's business, improving operational capabilities and market competitiveness, and expanding its product portfolio, particularly in green science chemistry.
• PFSPL, incorporated on April 13, 2021, is engaged in manufacturing speciality, aroma chemicals, and green science chemistry. It has an operational unit in Lote, Maharashtra, and land acquired in Jhagadia, Gujarat, for its green science business.
• PBPL is engaged in the manufacture, research, and development of biotechnology products, especially for flavours and fragrances.
• The amalgamation involves a share exchange ratio where every 1,000 fully paid equity shares of PFSPL (face value ₹10) will be exchanged for 7.9897 equity shares of PSCL (face value ₹10).
• The Proposed Scheme is subject to various approvals including from the National Company Law Tribunal (NCLT), Securities and Exchange Board of India (SEBI), Stock Exchanges (BSE and NSE), and the shareholders and creditors of PSCL, PFSPL, and PBPL.
• The company's shareholding pattern is expected to change upon the scheme becoming effective due to the issuance of securities to PFSPL shareholders.